Litigation Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Docket		Date Filed	2016-12-07
Court	District Court, D. Delaware	Date Terminated	2019-01-10
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To
Patents	9,439,900
Link to Docket	External link to docket

Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-07				External link to document
2016-12-06	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,439,900 B2. (jcs) (Entered:…2016 10 January 2019 1:16-cv-01138 830 Patent Defendant District Court, D. Delaware	External link to document

Orexo AB v. Actavis Elizabeth LLC, 1:16-cv-01138: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Orexo AB’s patent case against Actavis Elizabeth LLC concerned Actavis’ abbreviated new drug application for a generic version of Zubsolv, Orexo’s buprenorphine/naloxone sublingual tablet for opioid-dependence treatment. The dispute centered on U.S. Patent No. 8,940,330, which covered aspects of Zubsolv’s formulation and dosage composition. The U.S. District Court for the District of Delaware initially granted Orexo a preliminary injunction, but the Federal Circuit later reversed after holding that the asserted claims were likely obvious over the prior art. The appellate decision materially weakened the patent barrier to generic entry. [1]

What was Orexo AB v. Actavis Elizabeth LLC about?

Orexo sued Actavis after Actavis filed an ANDA seeking FDA approval to market a generic buprenorphine/naloxone sublingual tablet. Orexo alleged that the ANDA product would infringe claims of U.S. Patent No. 8,940,330, known as the ’330 patent.

Item	Detail
Court	U.S. District Court for the District of Delaware
Case number	1:16-cv-01138
District judge	Richard G. Andrews
Plaintiff	Orexo AB
Defendant	Actavis Elizabeth LLC, an Allergan/Actavis generic subsidiary
Product	Zubsolv buprenorphine/naloxone sublingual tablets
NDA	NDA 204242
Asserted patent	U.S. Patent No. 8,940,330
Filing year	2016
Federal Circuit citation	903 F.3d 1265 (Fed. Cir. 2018)
Principal issue	Infringement and obviousness of the ’330 patent
Appellate outcome	Preliminary injunction vacated and case remanded

The litigation was a Hatch-Waxman patent dispute. Actavis’ ANDA filing constituted an artificial act of infringement under 35 U.S.C. § 271(e)(2), allowing Orexo to sue before commercial launch.

What patent protected Zubsolv in the Actavis litigation?

The central patent was U.S. Patent No. 8,940,330, titled “Pharmaceutical composition.” The patent covered a sublingual formulation containing buprenorphine and naloxone, together with excipients and compositional limitations intended to produce a rapidly dissolving tablet.

The asserted claims included limitations relating to:

• Buprenorphine or a pharmaceutically acceptable salt;
• Naloxone or a pharmaceutically acceptable salt;
• Citric acid;
• Mannitol;
• A sublingual dosage form; and
• A specified buprenorphine-to-naloxone ratio.

The claimed formulation was directed to the type of tablet used in Zubsolv. Orexo positioned the patent as covering formulation improvements over earlier buprenorphine/naloxone products, particularly Suboxone tablets and films.

The ’330 patent issued Jan. 27, 2015. Its listed patent-term expiration was in December 2032. The patent’s remaining term was therefore commercially significant when Orexo sued Actavis in 2016.

When did Orexo sue Actavis, and what triggered the case?

Orexo filed the action in 2016 after receiving Actavis’ Paragraph IV certification. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product.

The filing of the Paragraph IV certification created the statutory basis for the patent action. Because Orexo filed suit within the applicable Hatch-Waxman period, FDA approval of the Actavis ANDA was subject to a statutory 30-month stay, unless the court resolved the dispute earlier or otherwise modified the stay.

The case was therefore both a patent-validity dispute and a potential market-entry event for generic buprenorphine/naloxone tablets.

What did the Delaware district court decide?

The district court granted Orexo’s motion for a preliminary injunction in 2017. The injunction prevented Actavis from commercially launching its proposed generic product while the case proceeded.

Orexo needed to show a likelihood of success on infringement and validity, irreparable harm, favorable equities, and consistency with the public interest. The district court found that Orexo had made the required showing, including a likelihood that Actavis’ product would infringe the asserted claims and that the claims would withstand Actavis’ obviousness challenge.

The preliminary-injunction ruling did not constitute a final determination after trial. It reflected the district court’s assessment of the record at an interim stage.

How did the Federal Circuit decide Orexo v. Actavis?

The Federal Circuit reversed the preliminary injunction. In Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265 (Fed. Cir. 2018), the appellate court held that the district court had erred in assessing obviousness.

The Federal Circuit agreed that the district court’s claim construction was not the central problem. The decisive issue was whether the prior art would have provided a skilled artisan with a reason to modify known buprenorphine/naloxone formulations in the claimed manner.

The appellate court considered prior-art references involving:

• Buprenorphine/naloxone combinations;
• Sublingual delivery;
• Excipients used in rapidly dissolving tablets;
• Citric acid and mannitol; and
• The relative dosage ratio of buprenorphine and naloxone.

The court concluded that the asserted claims were likely obvious. It held that the record showed a motivation to combine the relevant prior-art teachings and that the claimed formulation did not present a sufficiently unexpected technical result to overcome the obviousness case. [1]

The Federal Circuit vacated the preliminary injunction and remanded the matter to the district court.

Why was obviousness the critical issue?

Orexo’s patent strategy depended on treating the combination of known ingredients and known formulation techniques as a patentable improvement. Actavis argued that the claimed formulation was a predictable selection from existing buprenorphine/naloxone technology.

The Federal Circuit’s reasoning focused on whether the patent claimed more than the routine application of known formulation principles. The court treated several limitations as familiar in the field:

1. Buprenorphine and naloxone were already known in opioid-dependence treatment.
2. Sublingual administration was already established.
3. Mannitol and citric acid were known pharmaceutical excipients.
4. The claimed ratio fell within or near known ranges.
5. The formulation objectives were consistent with ordinary formulation development.

Orexo relied on asserted advantages, including tablet performance, dissolution characteristics, and reduced abuse-related concerns. The Federal Circuit found that the evidence did not establish a sufficient unexpected-results showing in relation to the full scope of the claims.

The decision illustrates the vulnerability of combination formulation patents when each individual component is known and the claimed result follows from predictable pharmaceutical development.

What was the Orange Book status of Zubsolv?

Zubsolv was approved by the FDA in July 2013 under NDA 204242. The product is a sublingual tablet containing buprenorphine hydrochloride and naloxone hydrochloride.

The ’330 patent was listed in the FDA’s Orange Book for Zubsolv. Its listing gave Orexo statutory leverage against ANDA applicants that certified under Paragraph IV.

The Orange Book listing did not establish that the patent was valid or enforceable. It created the regulatory and litigation framework for challenging the patent. The Federal Circuit’s obviousness ruling reduced the practical value of the listing against Actavis because the asserted claims could not reliably support an injunction.

FDA regulatory status

Zubsolv is an FDA-approved small-molecule drug product for opioid dependence treatment. The Actavis product would have proceeded through the ANDA pathway, not the biosimilar pathway.

The case did not involve:

• A biologic license application;
• A 351(k) biosimilar application;
• Biosimilar interchangeability;
• Patent dance procedures under the Biologics Price Competition and Innovation Act.

Biosimilar risk was therefore not a relevant competitive category. The commercial threat was conventional generic entry.

Did Actavis win the patent case?

Actavis prevailed on the key appellate issue at the preliminary-injunction stage. The Federal Circuit did not issue a broad final judgment declaring every possible claim of the ’330 patent invalid in every context. It held that the asserted claims were likely obvious and vacated the injunction.

The practical result was favorable to Actavis because Orexo lost the immediate court order blocking launch. The decision removed the principal judicial barrier that had prevented Actavis from proceeding during the litigation.

Procedural stage	Result
ANDA filing	Actavis submitted a Paragraph IV challenge
District court preliminary injunction	Granted for Orexo
Federal Circuit appeal	Reversed
Patent issue on appeal	Likely obviousness of asserted claims
Immediate commercial effect	Actavis was no longer subject to the preliminary injunction
Final broader patent status	Dependent on further district-court proceedings and any later resolution

What patent litigation affected Zubsolv generic entry?

The Actavis case was the principal reported appellate challenge involving the ’330 patent. Its importance extended beyond the named parties because a Federal Circuit obviousness ruling can affect the bargaining position of the patent owner against other ANDA applicants.

The decision created several entry risks for Orexo:

• Other generic applicants could rely on the same prior-art record.
• The patent owner’s ability to obtain preliminary injunctive relief declined.
• A Paragraph IV challenger gained leverage in settlement negotiations.
• The commercial value of the ’330 patent was reduced despite its long remaining term.
• A later patent or unasserted claim would have needed to supply a separate infringement barrier.

The decision did not automatically invalidate every other patent associated with Zubsolv. It directly addressed the asserted claims and the preliminary-injunction record in the Actavis proceeding.

What formulation patents protected Zubsolv?

The ’330 patent was a formulation patent rather than a patent covering the basic active ingredients alone. Buprenorphine and naloxone were known before the patent, and the commercial differentiation was based largely on the tablet formulation and delivery characteristics.

Formulation patent protection can cover:

• Excipient combinations;
• Particle or granule structure;
• Dissolution performance;
• Taste-masking systems;
• Dosage ratios;
• Sublingual delivery;
• Manufacturing conditions; and
• Stability or release characteristics.

In this case, the appellate outcome shows the weakness of a formulation claim where the prior art supplies the active ingredients, route of administration, excipients, and development rationale. The formulation may be commercially valuable even when the patent claim is legally vulnerable.

Was there a settlement agreement in the case?

The reported Federal Circuit decision does not identify a settlement agreement as the basis for disposition. The operative reported outcome was appellate reversal of the preliminary injunction and remand to the Delaware district court.

The public decision should not be treated as evidence of a later commercial launch date, a license, or a confidential settlement term. The appellate opinion establishes the legal ruling, not the complete commercial history of the parties’ post-remand relationship.

How strong was Orexo’s patent estate after the Federal Circuit ruling?

The ’330 patent had meaningful remaining term but reduced litigation strength after the Federal Circuit’s obviousness decision.

Strength factor	Assessment
Remaining patent term	Long, extending into 2032
Orange Book listing	Provided Hatch-Waxman litigation leverage
Claim type	Formulation claims tied to Zubsolv
Prior-art exposure	Significant
Preliminary-injunction record	Unfavorable after appeal
Generic entry risk	Elevated
Biosimilar exposure	Not applicable
Manufacturing barrier	Limited unless separate process claims applied
Settlement leverage	Reduced after reversal

Patent strength is not determined by expiration date alone. A long-dated patent with a Federal Circuit obviousness ruling against the asserted claims may provide less exclusionary value than a shorter patent with strong infringement and validity evidence.

What generic launch scenarios existed after the decision?

The Federal Circuit ruling created three commercially relevant scenarios.

Immediate or accelerated entry

Actavis could seek to proceed after the injunction was vacated, subject to the status of the 30-month stay, FDA approval, other listed patents, and any separate court order.

Delayed entry through settlement

Orexo could still negotiate a settlement providing a future entry date, license, or other commercial terms. The reversal would likely weaken Orexo’s negotiating position because Actavis had obtained a favorable appellate ruling on validity.

Continued litigation over other patents

Orexo could continue asserting other Orange Book-listed patents or pursue claims not resolved by the Federal Circuit decision. Any such action would require a separate infringement and validity analysis.

The decision therefore removed one major barrier but did not itself establish the precise date on which a generic product could enter the market.

How does Orexo v. Actavis compare with ordinary generic patent disputes?

The case is representative of high-value Hatch-Waxman formulation litigation in three respects.

First, the dispute arose before generic launch through a Paragraph IV certification. Second, the brand owner obtained interim relief in the district court but lost that protection on appeal. Third, the decisive question was not whether the generic product copied the marketed product, but whether the patent claims were valid and infringed under the statutory framework.

The case is less typical in that the appellate court addressed preliminary-injunction findings rather than issuing a final post-trial validity judgment. Its commercial effect was still substantial because preliminary injunctive relief often determines whether a generic can enter while litigation continues.

Key Takeaways

• Orexo sued Actavis in Delaware over an ANDA for a generic Zubsolv sublingual tablet.
• The central patent was U.S. Patent No. 8,940,330.
• The patent covered a buprenorphine/naloxone sublingual formulation with specified excipients and compositional limitations.
• The Delaware district court granted Orexo a preliminary injunction.
• The Federal Circuit reversed in 2018, holding that the asserted claims were likely obvious.
• The appellate decision removed the immediate injunction and increased generic entry risk.
• Zubsolv is an FDA-approved small-molecule product, so biosimilar law was not implicated.
• The ruling weakened the commercial value of the ’330 patent despite its listed expiration in December 2032.
• The reported appellate decision does not disclose a settlement agreement or establish a final commercial launch date.
• Any later entry analysis requires separate review of remaining Orange Book patents, FDA approval status, and post-remand proceedings.

FAQs About Orexo AB v. Actavis Elizabeth LLC

What drug was at issue in Orexo AB v. Actavis?

The case concerned Zubsolv, Orexo’s buprenorphine/naloxone sublingual tablet approved for opioid-dependence treatment.

What patent number did Orexo assert against Actavis?

Orexo principally asserted U.S. Patent No. 8,940,330, a formulation patent covering a buprenorphine/naloxone sublingual composition.

Did the Federal Circuit invalidate the Zubsolv patent?

The Federal Circuit held that the asserted claims were likely obvious and vacated the preliminary injunction. The decision was not framed as a universal invalidity judgment covering every possible claim or patent associated with Zubsolv.

Was Actavis’ product a biosimilar to Zubsolv?

No. Actavis’ product was a proposed generic drug submitted through the ANDA pathway. Zubsolv is a small-molecule product, not a biologic.

What was the commercial significance of the 2018 appellate ruling?

The ruling removed Orexo’s preliminary injunction and reduced the patent’s ability to delay generic entry. It also weakened Orexo’s position in any subsequent Hatch-Waxman settlement or licensing negotiations.

References

1. Orexo AB v. Actavis Elizabeth LLC, 903 F.3d 1265 (Fed. Cir. 2018).
2. U.S. Patent No. 8,940,330, “Pharmaceutical composition,” issued Jan. 27, 2015.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).
4. U.S. Food and Drug Administration. (2013). NDA 204242: Zubsolv approval materials.